Navigation Links
Former CEO of Eurofins Advantar Laboratories, Richard Kenley, PhD, joins NDA Partners as Expert Consultant
Date:5/18/2017

NDA Partners Chairman Carl Peck, MD, announced today that Richard Kenley, PhD, senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm as an Expert Consultant. In addition to his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and General Manager of the San Diego Facility of Magellan (acquired by Cardinal Health), and Founder and General Manager of Cabrillo Laboratories (acquired by Magellan). Dr. Kenley is a recognized industry leader with experience in R&D, start-up and in multinational corporate environments with expertise in small molecule and protein therapeutics, drug delivery systems and manufacturing.

In his early career, Dr. Kenley was Senior VP of Product Development at Amylin Pharmaceuticals; Director of Pharmaceutical Sciences, Genetics Institute; Associate Director of Chemistry R&D, Baxter Healthcare Corp.; Department Head, Pharmaceutical Analysis, Syntex Research; and Section Head, Medical Chemistry, Stanford Research Institute, International.

“Dr. Kenley’s extensive experience in the start-up and multinational corporate environments, in addition to his expertise in small molecule and protein therapeutics, drug delivery system development and manufacturing will provide an excellent resource to our clients,” said Dr. David Savello, Partner and Manager, Product Quality & CMC Practice. “We are very pleased to welcome him to NDA Partners.”

Dr. Kenley earned his PhD in Chemistry from the University of California, San Diego and his BSc in Chemistry from the University of Illinois Urbana-Champaign. He is a Fellow of the American Academy of Pharmaceutical Scientists, has four patents, and more than 60 peer-reviewed research publications.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle(at)ndapartners(dot)com

Read the full story at http://www.prweb.com/releases/2017/05/prweb14338284.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Former FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
2. Former P&G VP Appointed New Industry Expert at Verixs Advisory Board
3. Former Director of FDA Division of Biostatistics, Gregory Campbell, PhD, joins NDA Partners as Expert Consultant
4. Vinod Shah, PhD, Former Senior Research Scientist in FDA Office of Pharmaceutical Sciences, Joins NDA Partners as Expert Consultant
5. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
6. Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners
7. Repetitive Head Injuries May Not Cause Movement Problems for Former NFL Players
8. Dr. Deborah Wenkert Pediatrics Expert and Former Amgen Clinical Research Medical Director, Joins NDA Partners
9. Dr. John Norris, Former 2nd-in-Command at the US FDA, Calls Out the Need for Several Types of FDA Reforms – And Tools to Implement Them
10. Dr. Steven Brooks, Former FDA Medical Officer, Peripheral Vascular Device Branch, Office of Device Evaluation, Joins NDA Partners
11. Former Senior FDA Official to Conduct Popular ComplianceOnline Seminar on the FDA’s Import Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):